Compounds > cl 232468
Page last updated: 2024-11-07

cl 232468

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CL 232468: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID125982
CHEMBL ID1979181
SCHEMBL ID4885984
MeSH IDM0127955

Synonyms (23)

Synonym
1,4-bis((2-aminoethyl)amino)-5,8-dihydroxy-9,10-anthraquinone
NCI60_015291
nsc645017
nsc-645017
aead
1,4-bis(2-aminoethylamino)-5,8-dihydroxyanthracene-9,10-dione
96555-65-6
unii-ozx2bs7rj6
cl 232,468
9,10-anthracenedione, 1,4-bis((2-aminoethyl)amino)-5,8-dihydroxy-
cl 232468
ozx2bs7rj6 ,
1,4-bis[(2-aminoethyl)amino]-5,8-dihydroxyanthracene-9,10-dione
SCHEMBL4885984
1,4-bis[(2-aminoethyl)amino]-5,8-dihydroxyanthraquinone
CLVFWRBVFBUDQU-UHFFFAOYSA-N
CHEMBL1979181
DTXSID80242325
1,4-dihydroxy-5,8-bis-(2-amino-ethylamino)-anthracen-9,10-dione
1,4-bis((2-aminoethyl)amino)-5,8-dihydroxy-9,10-anthracenedione
Q27453982
9,10-anthracenedione, 1,4-bis((2-aminoethyl)amino)-5,8-dihydroxy
AKOS040751208
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1656533Stabilization of dsBE12 oligonucleotide (unknown origin) assessed as drug-DNA adduct formation at 5 to 50 uM incubated for 4 hrs in presence of formaldehyde using [gamma-32P]ATP by phosphorimaging analysis relative to control2020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features.
AID1656536Stabilization of dsBE17 oligonucleotide (unknown origin) assessed as drug-DNA adduct formation at 5 to 50 uM incubated for 4 hrs in presence of formaldehyde using [gamma-32P]ATP by phosphorimaging analysis2020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features.
AID1656521Stabilization of [32P]-labelled dsDNA (unknown origin) assessed as drug-DNA adduct formation by measuring adduct half life incubated for 12 hrs in presence of formaldehyde by phosphorimaging analysis2020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features.
AID1656532Binding affinity to dsBE45 oligonucleotide (unknown origin) assessed as drug-DNA adduct formation at 5 to 50 uM incubated for 4 hrs in presence of formaldehyde using [gamma-32P]ATP by phosphorimaging analysis2020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features.
AID1656522Stabilization of [32P]-labelled dsDNA (unknown origin) assessed as drug-DNA adduct formation at 5 uM in presence of formaldehyde incubated for 12 hrs by phosphorimaging analysis relative to control2020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features.
AID1656534Stabilization of dsBE15 oligonucleotide (unknown origin) assessed as drug-DNA adduct formation at 5 to 50 uM incubated for 4 hrs in presence of formaldehyde using [gamma-32P]ATP by phosphorimaging analysis2020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features.
AID1656537Stabilization of dsBE67 oligonucleotide (unknown origin) assessed as drug-DNA adduct formation at 5 to 50 uM incubated for 4 hrs in presence of formaldehyde using [gamma-32P]ATP by phosphorimaging analysis relative to control2020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features.
AID1656524Stabilization of [32P]-labelled dsDNA (unknown origin) assessed as drug-DNA adduct formation at 1 uM to 24 uM incubated for 12 hrs in presence of formaldehyde by phosphorimaging analysis2020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (75.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.47 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
mitoxantrone
Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.		3.3670dihydroxyanthraquinoneanalgesic;
antineoplastic agent
ConditionIndicatedRelationship StrengthStudiesTrials
Left Ventricular Dysfunction
[description not available]		02.610
Extrasystole, Ventricular
[description not available]		02.610
Cardiomyopathies, Primary
[description not available]		02.610
Cardiomyopathies
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).		02.610
Ventricular Dysfunction, Left
A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.		02.610
Trypanosomiasis
Infection with protozoa of the genus TRYPANOSOMA.		01.9710